Eli Lilly (LLY 2.95%) and Novo Nordisk (NVO 2.48%) benefit from innovative treatments for obesity and diabetes.
*Stock prices used were the afternoon prices of Jan. 5, 2025. The video was published on Jan. 7, 2025.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
By Parkev Tatevosian, CFA
–
Jan 8, 2025 at 10:29AM
NYSE: LLY
Eli Lilly
Market Cap
$722B
Today's Change
(2.95%) $21.85
Current Price
$761.92
Price as of August 1, 2025, 3:58 p.m. ET
About the Author
A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history. You'll often find him writing about stocks in the consumer goods and technology sectors.
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Stocks Mentioned
Eli Lilly
LLY
$761.92
(2.95%)
$21.85
Novo Nordisk
NVO
$48.23
(2.48%)
$1.17
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Eli Lilly Stock Topped the Market Today
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
Why Eli Lilly Stock Was Looking Sickly Today
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
The 3 Things That Matter for Eli Lilly Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.